Entrectinib (Rozlytrek®) is indicated as monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/09/2021|
|Rapid review completed||28/09/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that entrectinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.